Henry Schein, Inc., headquartered in Melville, N.Y., is a leading provider of healthcare products and services to office-based dental and medical practitioners. Founded by Henry Schein and Esther Schein in 1932, the company is now led by Stanley M. Bergman and has more than 19,000 employees worldwide. It serves more than one million customers globally.
Henry Schein’s operations are organized into two principal segments: healthcare distribution and technology. The healthcare distribution segment distributes consumables products, lab products, services, equipment, vaccines, pharmaceuticals, and surgical products. The technology segment provides software, technology, and other value-added services to its healthcare practitioners.
The company has a well-established reputation for being customer-centric. Henry Schein’s operations are guided by the belief in "doing well by doing good." It aids its customers to operate efficient practices while delivering high-quality care by providing a broad array of solutions, delivered by committed team Schein members.
What sets Henry Schein apart is its strong supply chain network, which spans North America, Europe, and the Asia-Pacific region. The company’s strong global footprint empowers it to reach more customers and tap into new markets. Its extensive product portfolio covers both generic and specialty drugs.
Henry Schein is also deeply invested in the communities it serves. Through its Henry Schein Cares program, the company funds various charitable initiatives globally that focus on increasing access to healthcare for underserved populations.
Furthermore, the company’s commitment towards sustainability is evident from its participation in eco-conscious initiatives. Henry Schein, Inc. is keen on promoting resource efficiency in its operations and reducing its carbon footprint with programs like the Henry Schein Green initiative.
The company operates under high standards of corporate governance and social responsibility, dedicating considerable resources to ethics and compliance programs. Henry Schein, Inc. is not only dedicated to its mission of delivering the best health to healthcare professionals—they go a step further to ensure the well-being and progress of communities surrounding their fields of operation.
Despite the challenges posed by the volatile economic environment, Henry Schein continues to show steady growth both organically and through strategic acquisitions. Its stock is listed on the NASDAQ Stock Market under the symbol "HSIC". Notably, it was also named as a Fortune World’s Most Admired Company for three consecutive years, from 2016-2018, a testament to its reliable business model and management caliber.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This article analyzes the Q2 performance of several dental equipment and technology stocks, highlighting Dentsply Sirona (XRAY), Envista (NVST), Align Technology (ALGN), and Henry Schein (HSIC). It details their revenue growth, performance against analyst estimates, and stock price reactions, noting that the sector experienced strong Q2 revenues but subsequent stock price declines. The piece also touches on broader market shifts, including concerns over AI and geopolitics impacting investor focus.
/Henry%20Schein%20Canada%20office%20building%20in%20Vaughan%20By%20JHVEPhoto.jpeg)
Henry Schein, Inc. (HSIC) is outperforming the Dow Jones Industrials Average ($DOWI) year-to-date and over the past 52 weeks, driven by strong internal sales, dental merchandise gains, and strategic acquisitions. The company's Q2 results exceeded Wall Street expectations for both EPS and revenue, contributing to a "Moderate Buy" rating from analysts. HSIC continues to focus on digital transformation and long-term growth through its BOLD+1 plan and investments in technology.
Henry Schein Inc. reported strong Q2 2026 financial results with significant sales and non-GAAP EPS growth, leading to an increased full-year guidance. The company highlighted strategic initiatives including AI-enabled technology platforms, accelerated sales of own-brand products, and medical business expansion. Value creation efforts are on track to achieve $200 million in operating income improvements, with a focus on enhancing customer experience and driving sustainable shareholder value.
Argus has lowered its target price for STERIS plc (Ireland) (STE) to $230.00. STERIS is a medical technology company specializing in sterilization services and infection prevention. The report was published on September 23, 2026.
Henry Schein, Inc. (HSIC) is a leading healthcare sector player with a market capitalization of $9.66 billion, serving dental and medical practitioners globally. Despite a recent stable stock movement, analysts project a 15.73% potential upside, with positive sentiment due to its attractive valuation, robust revenue growth, and strategic focus on innovation. The company's decision not to distribute dividends allows it to reinvest in growth and technology, making it a stock worth watching for investors.
Envista Holdings Corp. has launched Kerr consumables in India, marking the country as a strategic growth market due to increasing oral health awareness and demand for restorative treatments. This launch follows the opening of a new manufacturing facility in Suzhou, China, indicating Envista's broader focus on Asian expansion and increased regional production. The company plans to strengthen its presence in India through increased engagement with clinicians and educational initiatives.
_07_03_2026_03_50_21_133108.jpg)
Henry Schein's CEO of Global Distribution and Technology, Andrea Albertini, reported two stock disposals on September 8, 2026. These transactions included surrendering 603 shares to cover tax withholdings from vested performance-based restricted stock units and disposing of an additional 3,984 shares at no cost. Following these disposals, Albertini directly holds 116,104 shares of Henry Schein common stock.